RxDoctor Payments Data

Loren Vesselle, MD

Ophthalmology · Kirkland, WANPI 1548319791

Payments from drug & device makers

$1,694in general payments, 2019–2025

Across 21 payments — averaging $80.67 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Tarsus Pharmaceuticals, Inc.$249
  • Bausch & Lomb Americas Inc.$247
  • Oyster Point Pharma, Inc.$242
  • Carl Zeiss Meditec USA, Inc.$186
  • Dompe US, Inc.$172
  • Sun Pharmaceutical Industries Inc.$165
  • plus $433 from 5 others

What the payments were for

  • Food & beverage$1,67599%
  • Gifts$191%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

20
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,694 in reported general payments places this provider in the 65th percentile of 428 ophthalmology providers in Washington.

See all ophthalmology providers in Washington

Medicare billing

Part B allowed, 2024
$251,357
Medicare patients
612
Services billed
2,036

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OxervateCenegermin-Bkbj55$2,613,417
XiidraLifitegrast282$234,787
CequaCyclosporine297$195,895
RestasisCyclosporine245$195,568
XdemvyLotilaner73$134,581
TyrvayaVarenicline Tartrate109$90,714
MieboPerfluorohexyloctane/Pf59$47,141
VevyeCyclosporine34$41,110
Cyclosporine67$29,573
RhopressaNetarsudil Mesylate22$14,176
Restasis MultidoseCyclosporine16$13,394
Prednisolone Acetate360$11,449
Loteprednol Etabonate101$10,331
LumiganBimatoprost23$8,430
CombiganBrimonidine Tartrate/Timolol16$6,451

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Dompe US, Inc.Oxervate$172$2,613,41755 claims
Bausch & Lomb Americas Inc.Xiidra, Miebo$247$281,928341 claims
AbbVieRestasis, Restasis Multidose, Lumigan, Combigan$32$223,843300 claims
Sun Pharmaceutical Industries Inc.Cequa$165$195,895297 claims
Tarsus Pharmaceuticals, Inc.Xdemvy$249$134,58173 claims
Oyster Point Pharma, Inc.Tyrvaya$242$90,714109 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 428 ophthalmology providers in Washington.

Other ophthalmology in Kirkland

See the full list for Washington

Where these figures come from

Is this you, or does something look wrong? →